AXIS banner.jpg
 

AXIS (Access Extract Integrate Safe data)

AXIS are part of the NIHR Southampton Biomedical Research Centre (BRC) 5-year funding programme working within the Data Science Cross cutting theme. They have the ultimate mission to set up a framework where the clinical data extraction, transformation and integration with other research data could happen seamlessly and transparently. Creating safer data sharing and access. They aim to enhance the quality and quantity of clinical data extraction, making the process of obtaining clean and well-curated data from the clinical care services a much easier and obtainable process.

Dr Hang Phan, Data Science Lead & Florina Borca, Senior Information Analyst for Research & Development

Dr Hang Phan, Data Science Lead & Florina Borca, Senior Information Analyst for Research & Development

AXIS offer a range of services which include:

• Advanced data analysis, data extraction, cleaning, transformation and data validation

• Feasibility investigation support (Cohort estimation from hospital data and from national HES data, NHS Digital data exploration)

• Genomic data hosting in original file format (Fastq, BAM, VCF and other data format)

• Processed genomic data hosting (SQL) such as VCF, Genotyping chip, Transcriptomic, Metabolomics, Proteomics and Metagenomics.

Learn more about AXIS by contacting ciru@soton.ac.uk


“Accurate, longitudinal and thorough clinical data is a vital element of translating basic science findings into clinical practice. At Southampton our genetics of paediatric inflammatory bowel disease study has benefitted hugely from precise clinical data provided through working with the AXIS team. It has already enabled us to publish on novel clustering of patients based on blood results and determine that specific medication has had a significant impact on surgery rates in childhood inflammatory bowel disease. The future is even more exciting; this the data is now enabling us to incorporate genetic risk into clinical prediction, paving the way for personalising therapy in inflammatory bowel disease within the next 5 years.”

Dr James Ashton, Clinical Research Fellow in Paediatric IBD based in Human genetics and genomic Medicine, UHS, England, UK